Novavax (NVAX) Tops Q4 EPS by 60c
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $8.90 --0%
EPS Growth %: -164.5%
Financial Fact:
Loss from operations: -63.31M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -164.5%
Financial Fact:
Loss from operations: -63.31M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q4 EPS of $0.11, $0.60 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $147 million versus the consensus estimate of $90.25 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Travere Therapeutics (TVTX) PT Raised to $65 at Guggenheim
- Paychex (PAYX) PT Lowered to $98 at UBS on Lower Multiple Reflecting Uncertainty
- Qualcomm (QCOM) PT Raised to $235 at UBS: 'FY29 Target Model Revs Largely in Line'
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
